Document is current
Any future updates will be listed below
-
Authors
Molina-Collada, Juan https://orcid.org/0000-0001-5191-7802
Bellón, José María
Blanco-Cáceres, Boris https://orcid.org/0009-0009-4896-7011
Coronel, Luis https://orcid.org/0000-0002-5460-864X
de Agustín, Juan José https://orcid.org/0000-0001-7702-1625
Estrada, Paula https://orcid.org/0000-0002-9827-5680
Garmendia Sánchez, Elena https://orcid.org/0009-0008-9773-6319
García Vivar, M. Luz https://orcid.org/0000-0001-8822-9843
Olivas-Vergara, Otto https://orcid.org/0000-0003-1621-2692
Jiménez Núñez, Francisco Gabriel https://orcid.org/0000-0002-9403-6842
Mayordomo, Lucía https://orcid.org/0000-0001-9578-9507
Moragues, Carmen https://orcid.org/0000-0002-8459-7291
Rebollo-Giménez, Ana Isabel https://orcid.org/0000-0002-3973-3442
Uson, Jacqueline https://orcid.org/0000-0002-2933-4878
Vicente-Rabaneda, Esther F. https://orcid.org/0000-0001-6823-4194
Naredo, Esperanza https://orcid.org/0000-0003-0017-0096
,
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI20/00847, PI23/01226, RD24/0007/0029)
- License Information
-
More Information
Article History
Received: 27 December 2025
Accepted: 13 April 2026
First Online: 24 April 2026
Declarations
:
: The study protocol was approved by the Ethics Committee for Research with Medicines of Hospital General Universitario Gregorio Marañón, Madrid, Spain (PI-270/24). All patients signed a written informed consent prior to participation.
: Not applicable.
: Juan Molina-Collada has received consultancy/speaker’s fees from AbbVie, Lilly, Janssen, Novartis, Pfizer, UCB, MSD, and BMS; trial participation as principal investigator for Novartis. None of these fees were related to the present manuscript. Esperanza Naredo has received consultancy/speaker’s fees from Abbvie, Janssen, Novartis, Pfizer, and research grants from Lilly, Pfizer, and Abbvie. None of these fees were related to the present manuscript. Boris Blanco-Cáceres has received consultancy/speaker’s fees from Janssen, Novartis, Pfizer, UCB, MSD. None of these fees were related to the present manuscript. This work was partly supported by Grants: PI20/00847, PI23/01226, RD24/0007/0029 from Instituto de Salud Carlos III and co-financed by the European Regional Development Fund. Funds were used exclusively for statistical analysis expenses.
